Fig. 2

BRCA mutant cell lines are more susceptible to cisplatin and olaparib treatment. a Cytotoxicity Assay: PEO1 and PEO4 cells were treated with various concentrations of MK-2206, cisplatin, and olaparib. After 72 h, MTS solution was added and absorbance read at 490 nm after 4 h. Data are means ± SD. Survival is significantly different (p < 0.001) at all points with the exception of the 0.78 μM concentration of olaparib (p = 0.27). b Clonogenic Assay: SK-OV-3 NTC and BRCA1-kd cells were exposed continuously to various concentrations of MK-2206, cisplatin, and olaparib. After 13 days, colonies were stained and clonogenic survival was determined. Data are means ± SD